DOCSLIB.ORG

Thoratec Centrimag Blood Pump

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thoratec Centrimag Blood Pump CentriMag® Blood Pump INSTRUCTIONS FOR USE (IFU) READ ENTIRE CONTENTS PRIOR TO USING THE BLOOD PUMP Thoratec Clinical & Technical Support Phone number(s) Emergency HeartLine™ USA: Tel: +1-800-456-1477 United States Thoratec Corporation Tel: +1-925-847-8600 Main Switchboard: Fax: +1-925-847-8574 Emergencies outside USA: Tel: +1-925-847-8600 Outside United Urgent/24-Hour Europe: Tel: +44 (0) 7659 877901 States Thoratec Switzerland Tel: +41 (0) 44 275 7171 Main Switchboard: Fax +41 (0) 44 275 7172 Manufacturer: US Headquarters: Thoratec Switzerland GmbH Thoratec Corporation Technoparkstrasse 1 6035 Stoneridge Drive CH-8005 Zürich Pleasanton, CA 94588 Switzerland USA www.thoratec.com www.thoratec.com PL-0070 Rev 04 January 2013 DCO No 13-080 SUPPLIED STERILE AND READY FOR USE – INTENDED USE/INDICATIONS DO NOT USE IF PACKAGING IS DAMAGED OR ANY STERILE SEALS ARE BROKEN. The Thoratec CentriMag Blood Pump is indicated for use only with the Thoratec Console to pump WARNING (Definition) blood through the extracorporeal bypass circuit for extracorporeal circulatory support for periods Warnings are used if there is a potential for appropriate to cardiopulmonary bypass (up to six a serious hazard with misuse of the device, hours). It is also indicated for use in when special attention is required for extracorporeal support systems (for periods up to safety of the patient, or when special care six hours) not requiring complete should be exercised to prevent improper cardiopulmonary bypass (e.g. valvuloplasty, operation of the device that may cause circulatory support during mitral valve damage. reoperation, surgery of the vena cava or aorta, liver transplants etc.) This device is not designed, sold, or intended for use except as indicated. CAUTION (Definition) CONTRAINDICATIONS Cautions are used to alert the user to exercise special care for the safe use of This Thoratec CentriMag Blood Pumping System the device. is contraindicated for use as a cardiotomy suction device. It is also contraindicated for patients who are unable or unwilling to be treated DESCRIPTION with heparin. The Thoratec CentriMag Blood Pump has a WARNINGS spinning impeller that imparts rotary motion to the incoming blood, directing it through the 1. The Pump has not been qualified through in outflow port. The CentriMag Blood Pump is vitro, in vivo, or clinical studies for long-term intended for use in extracorporeal circulation use (longer than six hours) as a bridge-to- procedures and is designed to move blood by transplant or for pending recovery of the centrifugal force created by the rotating impeller. natural heart. The system is designed to allow improved blood handling and to decrease trauma, which may be 2. Instructions for Use and Manuals for all associated with extracorporeal circulatory related Thoratec extracorporeal devices support during cardiopulmonary bypass, by should be read prior to use. magnetically levitating the impeller and by eliminating seals and bearings. All pumps are 3. Possible side effects include, but are not sterilized before shipment. limited to: Infection, mechanical failure, hemolysis and thromboembolic phenomena. These are potential side effects with all extracorporeal blood systems. 4. Ensure that the Pump and circuit have been debubbled and primed properly prior to beginning bypass to minimize the risk of air reaching the patient. The use of an arterial filter is recommended. 5. Massive air entry into the Pump will cause the Pump to deprime and blood flow to stop. Stop the Pump and remove air prior to resuming circulation. Figure 1 – CentriMag Blood Pump 6. Do not expose to chemical agents as they may affect the integrity of this device. The CentriMag Blood Pump couples to a Anesthesia solutions such as forane are magnetic drive motor and console. The Blood known to degrade polycarbonate plastics. Pump, magnetic drive motor and console Avoid contact with these solutions with the comprise the Thoratec CentriMag Extracorporeal CentriMag Blood Pump. Blood Pumping System. 7. To prevent backflow of the patient’s blood This device is not designed or intended for use when the pump outlet tubing is open, except as indicated. establish and maintain a minimum pump Thoratec CentriMag® Blood Pump IFU Page 2 of 7 © 2013 Thoratec Switzerland GmbH – Document No PL-0070, Rev 04 (October 2013) speed that overcomes line and patient with attendant risk of death or severe bodily resistance. Failure to do this could allow injury. A massive air embolus will deprime retrograde flow and exsanguinate the patient. the Pump, halting outflow. 8. Arterial lines must be clamped when the 20. Do not restart the Pump if the Pump has Pump is at rest to prevent retrograde flow. been stopped for more than five minutes. The pump should also not be restarted after 9. It is intended that systemic anticoagulation it has stopped due to motor overheating. be utilized while this device is in use. Anticoagulation levels should be determined 21. Use of this Pump for periods longer than by the physician based on risks and benefits durations appropriate to cardiopulmonary to the patient. bypass procedures may result in pump failure, reduced pumping capacity, excessive 10. The Thoratec CentriMag Blood Pump is blood trauma, degradation of blood contact designed to be operated only with the materials with possibility of particles passing Thoratec drive console. There are no safety through the blood circuit to the patient, leaks, or performance data known to Thoratec and increased potential for gaseous emboli. which establishes compatibility of any other manufacturer’s devices or components to the CAUTIONS CentriMag Blood Pumping System. 1. Federal (U.S.A.) law restricts this device to 11. Potential risk to the patient should be sale, distribution and use by or on the order evaluated prior to changing the Pump. of a physician. 12. Frequent patient and device monitoring is 2. This device should only be used by persons recommended; do not leave the device thoroughly trained in extracorporeal unattended while in use. circulation procedures. 13. Do not use the CentriMag Blood Pump if the 3. Do not hit or strike the Pump with hands or Use By Date on the package has expired. instruments. Shock may cause damage to the device, which may cause device 14. Do not operate the Pump for more than 30 malfunction. seconds in the absence of flow. The temperature within the Pump will rise and 4. The CentriMag Blood Pump is sterile in an increased cellular damage and clotting may unopened and undamaged unit package. result. Inspect device and package carefully prior to use. Do not use if the unit package or the 15. The Pump must be handled and used in an product has been damaged or soiled. aseptic manner. 5. Each Pump is intended for single use only. 16. Do not operate the Pump with its inlet Do not resterilize. Resterilization by any clamped as a negative pressure would be means may cause severe damage to the generated in the Pump and air bubbles may device or its components. Dispose of safely be formed in the blood. after single use to avoid risk of infection. 17. The Pump contains a magnet. To avoid 6. Attach tubing in such a manner as to prevent injury, keep all sharp metal objects and kinks or any restrictions that may alter flow. instruments at least six inches away for the Pump. Do not remove the Pump from its 7. All tubing connections must be secured with inner tray until ready to insert into the motor standard sta-straps or tie wraps. receptacle. 8. Ensure the Pump is properly locked into the 18. If the Pump stops, clamp the venous and motor per the Directions for Use supplied arterial lines and check for air in the arterial with the Motor. line due to retrograde flow: remove air, attain a Pump speed adequate to overcome the 9. Monitor carefully for any signs of occlusion circuit resistance and then unclamp the lines. throughout the circuit. 19. Monitor the arterial line for air because the 10. Do not operate this Pump when unprimed as Thoratec CentriMag Blood Pump, similar to it may damage the impeller. other centrifugal pumps, will pump air. Stop infusion if air enters the Pump as gaseous 11. Run the Pump only on a properly maintained emboli may be introduced into the patient, Thoratec drive console and motor. Thoratec CentriMag® Blood Pump IFU Page 3 of 7 © 2013 Thoratec Switzerland GmbH – Document No. PL-0070, Rev. 04 (January 2013) 12. Do not use the Pump if dropped. Dropping or the fittings on the motor receptacle. Rotate other severe shock may cause damage counterclockwise until the Pump locks which could lead to device malfunction. securely into place. Thread the retaining screw clockwise to secure in place. The 13. Do not use excessive force to install tubing Pump must be fully seated into the on Pump as damage to Pump may occur. receptacle to function properly. To remove, unthread the retaining screw 14. Take care to prevent damage to connectors counterclockwise. Rotate the pump when repositioning prior to attaching tubing. clockwise until the grooves are matched. Lift and remove the pump. 15. Always have a spare CentriMag Blood Pump, back-up Console and equipment 3. Assemble the extracorporeal circuit; be sure available for change out. to connect the inlet and outlet tubing to the correct pump inlet and outlet. Connect 3/8 16. Do not place Pump near items adversely inch (9,5mm) Inner Diameter (ID) x minimum affected by magnetic fields. 3/32 inch (2,4mm) wall tubing from the reservoir outlet to the pump inlet. Attach 3/8 17. Monitor the Pump and replace it if there are inch (9,5mm) ID tubing to the pump outlet. fluid leaks or noisy operation.
Load more

Recommended publications
  • 2021 Annual Report Abiomed Fy 2021 Annual Report Annual 2021 Fy
    FY 2021 ANNUAL REPORT ABIOMED FY 2021 ANNUAL REPORT I AM ABIOMED I AM HEART RECOVERY 81% $848 82% $651 83% $513 83% 18 19 20 21 $400 Gross Margin Gross DOLLARS IN MILLIONS IN DOLLARS Net Cash Balances* 17FY 84% $277 17 18 19 20 21 FY 16 $848 +1% $230 $841 +9% $249 $769 +30% $225 $594 +33% 18 19 20 21 $157 DOLLARS IN MILLIONS IN DOLLARS DOLLARS IN MILLIONS IN DOLLARS Total Revenue Total 17 18 19 20 21 $445 +35% 17FY $90 GAAP Operating Income Operating GAAP FY Fiscal Year Ends March 31st Ends March Fiscal Year FY 2021 - COVID YEAR - COVID FY 2021 FINANCIAL PERFORMANCE * Net cash balances are defined as total cash, short-term and long-term marketable securities. The Company currently has no debt. 1 996 940 1,150 789 720 850 568 541 653 18 19 20 21 470 311 317 18 19 20 21 411 241 274 PATENTS PENDING PATENTS Total Impella Publications Total FY 17 FY 17 Total Abiomed Patent Portfolio Abiomed Patent Total $122 1,509 21 $99 1,441 $94 1,362 DEVICE PROGRESS ® 18 19 20 21 $75 1,197 18 19 20 DOLLARS IN MILLIONS IN DOLLARS $66 1,138 Sites Impella U.S. Total FY 17 FY 17 Research & Development Spend & Development Research IMPELLA YEAR - COVID FY 2021 31st Ends March Fiscal Year FY21 HIGHLIGHTS Q1 Q2 4/29/2020 5/27/2020 7/16/2020 Abiomed Expands Abiomed Hosts Virtual FDA Approves Data Product Portfolio with Clinical Data and Streaming from the Acquisition of Cardio- Innovation Day Impella Console, pulmonary Support Setting the Stage for Technology (ECMO) Artificial Intelligence 6/01/2020 Algorithms FDA Issues 6/05/2020 5/19/2020 EMERGENCY USE FDA Approves
    [Show full text]
  • Heartmate II® LVAS LEFT VENTRICULAR ASSIST SYSTEM
    HeartMate II® LVAS LEFT VENTRICULAR ASSIST SYSTEM OPERATING MANUAL Corporate Headquarters Authorized EU Representative Thoratec Corporation Thoratec Europe Limited 6035 Stoneridge Drive Burnett House, Lakeview Court Pleasanton, CA 94588 Ermine Business Park USA Huntingdon, Cambs PE29 6UA UK Business: Business: Tel.: 925-847-8600 Tel.: +44(0) 1480 455200 Fax: 925-847-8574 Fax: +44(0) 1480 454126 Emergencies: Urgent/24-Hour: 800-456-1477 (USA HeartLine™) +44(0) 7659 877901 925-847-8600 (International) www.thoratec.com 103884.C 12/2009 FOREWORD This manual contains information needed to properly and safely operate the Thoratec HeartMate II® Left Ventricular Assist System (LVAS). The Operating Manual and the Instructions for Use are intended to serve as both clinical textbook and reference; the new user should read both documents in their entirety, before system operation. For experienced practitioners, this manual may serve as a reference for detailed information. Users of the HeartMate II LVAS should have a practical knowledge of the principles of mechanical circulatory assist support (MSC) and should be aware of the physiological and psychological needs of a patient undergoing mechanical ventricular support. Sections 1-3 offer the reader an overall perspective of the system. They also describe the indications for use and the contraindications. Lastly, these sections introduce some of the unique attributes of the HeartMate II LVAS. Sections 4-11 explain how the system works, describe the technical features and operation of each system component and include descriptions of a variety of situations likely to arise during and after pump implantation. Sections 12-13 describe in detail the procedures necessary to support HeartMate II LVAS patients, including equipment cleaning and maintenance requirements.
    [Show full text]
  • Instructions for Use
    Instructions for Use Featuring the Mobile Power Unit Thoratec Corporation HEARTMATE II® LEFT VENTRICULAR ASSIST SYSTEM Instructions for Use United States & Canada Thoratec Corporation (International Headquarters) 6035 Stoneridge Drive Pleasanton, CA 94588 USA Telephone: (925) 847-8600 Fax: (925) 847-8574 Emergency HeartLine™ USA: (800) 456-1477 Emergencies outside USA: (925) 847-8600 Authorized EU Representative European Authorized Representative: St. Jude Medical Coordination Center BVBA The Corporate Village Da Vincilaan 11 Box F1 1935 Zaventem Belgium +32 2 774 68 11 Website: www.thoratec.com Thoratec Corporation continually strives to provide the highest quality of products for mechanical circulatory support. Specifications may change without notice. HeartMate II, Thoratec, and the Thoratec logo are registered trademarks, and HeartLine is a trademark of Thoratec Corporation. ©2016 Thoratec Corporation. Document: 10006961.B Publication Date: 03/2019 HeartMate II Left Ventricular Assist System Instructions for Use iii Contents Preface- - - - - - - - - - - - - - - - - - - - - - - ix 1 Introduction - - - - - - - - - - - - - - - - - - - - 1-1 Understanding Warnings and Cautions - - - - - - - - - - - - - - - - - - - - 1-3 Overview - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1-4 Indications - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1-6 Contraindications - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1-6 Adverse Events - - - - - - - - - - - - - - - - - - - - - - - - - - -
    [Show full text]
  • Thoratec Corporation
    · UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549-4561 January 27,2012 Charles K. Ruck Latham & Watkins LLP charles.ruck@lw.com Re: Thoratec Corporation Dear Mr. Ruck: This is in regard to your letter dated January 25,2012 concerning the shareholder proposal submitted by Oracle Partners, LP for inclusion in Thoratec's proxy materials for its upcoming annual meeting of security holders. Your letter indicates that the proponent has withdrawn the proposal and that Thoratec therefore withdraws its January 17,2012 request for a no-action letter from the Division. Because the matter is now moot, we will have no further comment. Copies ofall ofthe correspondence related to this matter will be made available on our website at http://www.sec.gov/divisions/corpfinlcf-noactionl14a-S.shtml. For your reference, a brief discussion ofthe Division's informal procedures regarding shareholder proposals is also available at the same website address. Sincerely, Charles K won Special Counsel cc: LarryN. Feinberg Managing Member Oracle Associates, LLC 200 Greenwich Avenue Greenwich, CT 06830 650 Town Center Drive. 20th Floor Costa Mesa. California 92626-1925 Tel:·+1.714.540.1235 Fax: +1.714.755.8290 www.lw.com FIRM I AFFILIATE OFFICES NSLLP LATHAM&WATKI Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Boston New York Brussels Orange County Chicago Paris Doha Riyadh Dubai Rome Frankfurt San Diego January 25, 2012 Hamburg San Francisco Hong Kong Shanghai Houston Silicon Valley London Singapore Los Angeles Tokyo VL4EMAIL Madrid washington. D.C. Milan U.S. Securities and Exchange Commission Division ofCorporation Finance Office of Chief Counsel 100 F Street, N.E.
    [Show full text]
  • 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
    Case3:14-cv-00360 Document1 Filed01/24/14 Page1 of 36 LIONEL Z. GLANCY (#134180) 1 MICHAEL GOLDBERG (#188669) 2 ROBERT V. PRONGAY (#270796) GLANCY BINKOW & GOLDBERG LLP 3 1925 Century Park East, Suite 2100 Los Angeles, California 90067 4 Telephone: (310) 201-9150 5 Facsimile: (310) 201-9160 E-mail: info@glancylaw.com 6 lglancy@glancylaw.com mmgoldberg@glancylaw.com 7 rprongay@glancylaw.com 8 Attorneys for Plaintiff 9 [Additional Counsel on Signature Page] 10 11 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 12 BRADLEY COOPER, Individually and On ) Case No. 13 Behalf of All Others Similarly Situated, ) 14 ) CLASS ACTION P l a i n t i f f s , ) 15 ) COMPLAINT FOR VIOLATIONS v. ) OF FEDERAL SECURITIES 16 ) LAWS THORATEC CORPORATION, GERHARD F. 17 ) BURBACH, TAYLOR C. HARRIS, and ) DEMAND FOR JURY TRIAL 18 ROXANNE OULMAN, ) ) 19 Defendants. ) 20 21 22 23 24 25 26 27 28 Case3:14-cv-00360 Document1 Filed01/24/14 Page2 of 36 CLASS ACTION COMPLAINT 1 2 Plaintiff Bradley Cooper (“Plaintiff”), individually and on behalf of all other persons similarly 3 situated, by his undersigned attorneys, for his complaint against defendants, alleges the following based 4 upon personal knowledge as to himself and his own acts, and information and belief as to all other 5 matters, based upon, inter alia, the investigation conducted by and through his attorneys, which 6 included, among other things, a review of the defendants’ public documents, conference calls and 7 announcements made by defendants, United States Securities and Exchange Commission (“SEC”) 8 9 filings, wire and press releases published by and regarding Thoratec Corporation (“Thoratec” or the 10 “Company”), analysts’ reports and advisories about the Company, and information readily obtainable 11 on the Internet.
    [Show full text]
  • Risk Assessment and Comparative Effectiveness of Left Ventricular
    JACC: HEART FAILURE VOL. - ,NO.- ,2017 ª 2017 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 2213-1779/$36.00 PUBLISHED BY ELSEVIER http://dx.doi.org/10.1016/j.jchf.2017.02.016 Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients The ROADMAP Study 2-Year Results Randall C. Starling, MD, MPH,a Jerry D. Estep, MD,b Douglas A. Horstmanshof, MD,c Carmelo A. Milano, MD,d Josef Stehlik, MD, MPH,e Keyur B. Shah, MD,f Brian A. Bruckner, MD,b Sangjin Lee, MS, MD,g c e f h James W. Long, MD, PHD, Craig H. Selzman, MD, Vigneshwar Kasirajan, MD, Donald C. Haas, MD, i j j d Andrew J. Boyle, MD, Joyce Chuang, PHD, David J. Farrar, PHD, Joseph G. Rogers, MD, for the ROADMAP Study Investigators ABSTRACT OBJECTIVES The authors sought to provide the pre-specified primary endpoint of the ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients) trial at 2 years. BACKGROUND The ROADMAP trial was a prospective nonrandomized observational study of 200 patients (97 with a left ventricular assist device [LVAD], 103 on optimal medical management [OMM]) that showed that survival with improved functional status at 1 year was better with LVADs compared with OMM in a patient population of ambulatory New York Heart Association functional class IIIb/IV patients. METHODS The primary composite endpoint was survival on original therapy with improvement in 6-min walk distance $75 m. RESULTS Patients receiving LVAD versus OMM had lower baseline health-related quality of life, reduced Seattle Heart Failure Model 1-year survival (78% vs.
    [Show full text]
  • Cardiac Assist Devices
    Cardiac Assist Devices Current and Pipeline Products GDME1006FPR / Published March 2013 Table of Contents 1 Table of Contents 1 Table of Contents ............................................................................................................... 2 1.1 List of Tables ............................................................................................................... 7 1.2 List of Figures ........................................................................................................... 13 2 Introduction ....................................................................................................................... 14 2.1 Catalyst ..................................................................................................................... 14 3 Competitive Assessment ................................................................................................... 16 3.1 Cardiac Assist Device Market, Comparison of Key Marketed Products ...................... 16 3.2 Ventricular Assist Devices Market, Key Company Share ............................................ 18 3.3 Ventricular Assist Devices, Comparison based on Pump Technology ........................ 19 3.4 Ventricular Assist Devices ......................................................................................... 20 3.4.1 Overview............................................................................................................. 20 3.4.2 First-Generation Devices ....................................................................................
    [Show full text]
  • IMACS Implant Printable Form
    Implant Device Information Additional indication for VAD: Failure to wean from CPB Post Cardiac Surgery None Enter cardiac operation: Device Type: LVAD RVAD Both (in the same OR visit) Total Artificial Heart Implant Date: Device Type (LVAD) Device Brand: Berlin Heart EXCOR Adult Berlin Heart EXCOR Pediatric Berlin Heart INCOR Circulite Synergy EvaHeart LVAS Heartmate II LVAS Heartmate IP Heartmate VE Heartmate XVE Heartware HVAD Jarvik 2000 Levacor LVAD Medos VAD Micromed Debakey VAD – Child Micromed HeartAssist 5 Novacor PC Novacor PCq Terumo Duraheart Thoratec IVAD Thoratec PVAD Device Type (RVAD) Device Brand: Berlin Heart EXCOR Adult Berlin Heart EXCOR Pediatric Berlin Heart INCOR Heartware HVAD Jarvik 2000 Medos VAD Thoratec IVAD Thoratec PVAD 1 of 3 Device Type – Total Artificial Heart Device Brand: SynCardia CardioWest AbioCor TAH Associated Findings (Surgical PFO/ASD observations or Intraoperative TEE): Aortic Insufficiency Tricuspid Insufficiency None Aortic Insufficiency: Mild Moderate Severe Tricuspid Insufficiency: Mild Moderate Severe Antibiotic Prophylaxis at time of Yes implant: No Unknown If yes, Select antibiotics/antifungals Amikacin days: ____________ given as prophylaxis at the Amphotericin days: ____________ time of Implant: Anidulafungin days: ____________ Aztreonam days: ____________ Caspafungin days: ____________ Cefazolin days: ____________ Cefuroxime days: ____________ Ceftazidime days: ____________ Ceftriaxone days: ____________ Cefepime days: ____________
    [Show full text]
  • Results of a Multicenter Clinical Trial with the Thoratec Implantable Ventricular Assist Device*
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE Slaughter et al Cardiopulmonary Support and Physiology provided by Elsevier - Publisher Connector Results of a multicenter clinical trial with the Thoratec Implantable Ventricular Assist Device* Mark S. Slaughter, MD,a Steven S. Tsui, MD,b Aly El-Banayosy, MD,c Benjamin C. Sun, MD,d Robert L. Kormos, MD,e Dale K. Mueller, MD,f H. Todd Massey, MD,g Timothy B. Icenogle, MD,h David J. Farrar, PhD,i and J. Donald Hill, MD,j on behalf of the IVAD Study Group Objective: The Thoratec Implantable Ventricular Assist Device (Thoratec Corpo- Supplemental material is ration, Pleasanton, Calif) can be used for univentricular or biventricular support in available online. patients with a body surface area as low as 1.3 m2. Results of the multicenter clinical trial are reviewed. Methods: Between October 2001 and June 2004, a total of 39 patients at 12 institutions were supported with the Thoratec Implantable Ventricular Assist De- vice. Twenty-four patients (62%) received left ventricular assist devices and 15 (38%) received biventricular assist devices. Indications included bridge to trans- plantation (n ϭ 30) and postcardiotomy failure (n ϭ 9). The control group included 100 patients from the Food and Drug Administration approval submissions for the paracorporeal version of the ventricular assist device. From Advocate Christ Medical Center, Oak Results: Twenty-eight male and 11 female patients, with mean age of 48 years a Lawn, Ill ; Papworth Hospital, Cambridge, (16–71 years) and body surface area of 1.9 m2 (1.3–2.4 m2) were supported for 3938 UKb; Heart Center NRW, Bad Oeynhausen, Germanyc; Ohio State University, Colum- patient-days (10.8 patient-years).
    [Show full text]
  • Thoratec® Because There Are More Than Two Sides to the Story THORATEC CORPORATION
    Products & Technology Thoratec® Because there are more than two sides to the story THORATEC CORPORATION THORATEC LABORATORIES AND THERMO CARDIOSYSTEMS HAVE MERGED TO CREATE A NEW COMPANY OFFERING SURGEONS, CARDIOLOGISTS AND HOSPITALS THE WIDEST RANGE OF CIRCULATORY SUPPORT SOLUTIONS AVAILABLE FOR THE TREATMENT OF CONGESTIVE HEART FAILURE. Table of Contents Introduction ...............................................1 More Ways to Manage CHF..........................2 HeartMate® LVAS ........................................4 Thoratec® VAD System ................................6 Thoratec Vascular Graft Products .................8 Support and Technology Resources ............10 ITC Products ............................................12 We offer the widest range of circulatory support solutions. More than a Cardiac Assist Company Cardiovascular diseases are the world’s leading cause of death. One of the most prevalent is Congestive Heart Failure (CHF). In the U.S. alone, an estimated five million people suffer from CHF, with another half-million or more diagnosed each year. The five-year mortality rate is estimated at 50 percent. Thoratec is committed to lowering that figure. In that effort, we provide two complementary cardiac assist product lines—the Thoratec Ventricular Assist Device (VAD) System for short-term cardiac support and the HeartMate Left Ventricular Assist System (LVAS) for longer-term support. Together, these products address more indications than the products of any other cardiac assist device company. Our cardiac assist products, along with our unique family of vascular grafts, our ITC blood coagulation measurement products, and a large and growing pipeline of next-genera- tion devices in clinical trials or under development, make Thoratec a central resource for treatment offerings for cardiac surgeons, cardiologists and their patients. More Ways to Manage CHF More than short-term heart failure assistance.
    [Show full text]
  • Bradley Cooper, Et Al. V. Thoratec Corporation, Et Al. 14-CV-00360
    Case4:14-cv-00360-CW Document28 Filed06/20/14 Page1 of 67 Lionel Z. Glancy (#134180) 1 Michael Goldberg (#188669) 2 Robert V. Prongay (#270796) GLANCY BINKOW & GOLDBERG LLP 3 1925 Century Park East, Suite 2100 Los Angeles, California 90067 4 Telephone: (310) 201-9150 5 Facsimile: (310) 201-9160 E-mail: info@glancylaw.com 6 Liaison Counsel for Lead Plaintiff and the Class 7 8 Jeremy A. Lieberman Patrick V. Dahlstrom POMERANTZ LLP Leigh Handelman Smollar 600 Third Avenue, 20th Floor Mark Bryan Goldstein New York, New York 10016 POMERANTZ LLP Telephone: (212) 661-1100 Ten South La Salle Street, Suite 3505 11 Facsimile: (212) 661-8665 Chicago, Illinois 60603 12 Telephone: (312) 377-1181 Facsimile: (312) 377-1184 pdahlstrom@pomlaw.com lsmollar@pomlaw.com mbgoldstein@pomlaw.com Counsel for Lead Plaintiff and the Class UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION BRADLEY COOPER, Individually and On Case No. 4:14-cv-00360-CW Behalf of All Others Similarly Situated, CLASS ACTION Plaintiffs, AMENDED CLASS ACTION v. COMPLAINT FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS THORATEC CORPORATION, GERHARD F. BURBACH, TAYLOR C. HARRIS, and DEMAND FOR JURY TRIAL ROXANNE OULMAN, Defendants Case4:14-cv-00360-CW Document28 Filed06/20/14 Page2 of 67 Lead Plaintiff Bradley Cooper (“Plaintiff”), individually and on behalf of all others similarly 1 2 situated, by his undersigned attorneys, for the Amended Complaint against Defendants Thoratec 3 Corporation (“Thoratec” or the “Company”), Gerhard F. Burbach (“Burbach”), Taylor C.
    [Show full text]
  • Current State-Of-The-Art of Device Therapy for Advanced Heart Failure
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Harvard University - DASH Current state-of-the-art of device therapy for advanced heart failure The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Lee, Lawrence S., and Prem S. Shekar. 2014. “Current state-of- the-art of device therapy for advanced heart failure.” Croatian Medical Journal 55 (6): 577-586. doi:10.3325/cmj.2014.55.577. http://dx.doi.org/10.3325/cmj.2014.55.577. Published Version doi:10.3325/cmj.2014.55.577 Accessed February 17, 2015 11:31:15 AM EST Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13890710 Terms of Use This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms- of-use#LAA (Article begins on next page) ADVANCED HEART FAILURE 577 Croat Med J. 2014;55:577-86 doi: 10.3325/cmj.2014.55.577 Current state-of-the-art of Lawrence S. Lee, Prem S. Shekar device therapy for advanced Division of Cardiac Surgery, Brigham and Women’s Hospital, heart failure Harvard Medical School, Boston, MA, USA Heart failure remains one of the most common causes of morbidity and mortality worldwide. The advent of me- chanical circulatory support devices has allowed signifi- cant improvements in patient survival and quality of life for those with advanced or end-stage heart failure.
    [Show full text]